Sugi Predict

Sugi Predict / Compounds / SCHEMBL6450045

SCHEMBL6450045

SCHEMBL6450045

OC[C@H]1OC2OC2[C@@H](O)[C@@H]1O

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.67
▸ TSHR P16473 2/20 0.67
▸ LMNA P02545 1/20 0.67
▸ TDP1 Q9NUW8 1/20 0.67
▸ TXNRD1 Q16881 6/20 0.59
▸ TXNRD3 Q86VQ6 6/20 0.59
▸ TXNRD2 Q9NNW7 6/20 0.59
▸ LGALS1 P09382 2/20 0.46
▸ LGALS3 P17931 2/20 0.46
▸ LGALS9 O00182 1/20 0.46
▸ LGALS8 O00214 1/20 0.46
▸ HDAC3 O15379 1/20 0.37
▸ HDAC1 Q13547 1/20 0.37
▸ HDAC2 Q92769 1/20 0.37
▸ HDAC8 Q9BY41 1/20 0.37
▸ HDAC6 Q9UBN7 1/20 0.37
▸ CA12 O43570 3/20 0.37
▸ CA1 P00915 3/20 0.37
▸ CA2 P00918 3/20 0.37
▸ CA9 Q16790 3/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4911677 1.00 ALDH1A1 (0.67) ALDH1A1TSHRLMNATDP1TXNRD1
SCHEMBL6266510 1.00 ALDH1A1 (0.67) ALDH1A1TSHRLMNATDP1TXNRD1
SCHEMBL28471882 1.00 ALDH1A1 (0.67) ALDH1A1TSHRLMNATDP1TXNRD1
SCHEMBL1193222 1.00 ALDH1A1 (0.67) ALDH1A1TSHRLMNATDP1TXNRD1
SCHEMBL18736267 1.00 ALDH1A1 (0.67) ALDH1A1TSHRLMNATDP1TXNRD1
SCHEMBL16016300 1.00 ALDH1A1 (0.67) ALDH1A1TSHRLMNATDP1TXNRD1
SCHEMBL4911680 1.00 ALDH1A1 (0.67) ALDH1A1TSHRLMNATDP1TXNRD1
SCHEMBL4911675 1.00 ALDH1A1 (0.67) ALDH1A1TSHRLMNATDP1TXNRD1
SCHEMBL890314 1.00 ALDH1A1 (0.67) ALDH1A1TSHRLMNATDP1TXNRD1
SCHEMBL4070795 0.92 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2015177083-A1 STEREOSELECTIVE SYNTHESIS OF INTERMEDIATES IN THE PREPARATION OF ß-C-ARYLGLUCOSIDES LEK PHARMACEUTICALS D.D. (SI) 2015-11-26 — — WO claimed
EP-2947077-A1 Stereoselective synthesis of intermediates in the preparation of ß-C-arylglucosides LEK Pharmaceuticals d.d. (SI) 2015-11-25 — — EP claimed
CN-109111490-B Halogenated pivaloyl glucopyranose and preparation method thereof for SGLT2 inhibitor 浙江大学 2021-02-23 — — CN disclosed
EP-2776449-B1 PROCESS FOR THE PREPARATION OF BETA-C-ARYL GLUCOSIDES SCINOPHARM TAIWAN LTD (TW) 2017-08-02 — — EP disclosed
CN-103974964-B Process for preparing beta-C-aryl glucosides SCINOPHARM TAIWAN, LTD. (CN) 2016-03-23 — — CN disclosed
WO-2015177083-A1 STEREOSELECTIVE SYNTHESIS OF INTERMEDIATES IN THE PREPARATION OF ß-C-ARYLGLUCOSIDES LEK PHARMACEUTICALS D.D. (SI) 2015-11-26 — — WO disclosed
EP-2947077-A1 Stereoselective synthesis of intermediates in the preparation of ß-C-arylglucosides LEK Pharmaceuticals d.d. (SI) 2015-11-25 — — EP disclosed
US-8952139-B2 Process for the preparation of β-C-aryl glucosides SCINOPHARM TAIWAN, LTD (TW) 2015-02-10 — — US disclosed
EP-2776449-A2 PROCESS FOR THE PREPARATION OF beta-C-ARYL GLUCOSIDES Scinopharm Taiwan Ltd. (TW) 2014-09-17 — — EP disclosed
CN-103974964-A Process for preparing beta-C-aryl glucosides SCINOPHARM TAIWAN LTD 2014-08-06 — — CN disclosed
US-20140128595-A1 Process for the Preparation of ß-C-Aryl Glucosides SCINOPHARM TAIWAN, LTD. (TW) 2014-05-08 — — US disclosed
WO-2013068850-A2 PROCESS FOR THE PREPARATION OF β-C-ARYL GLUCOSIDES SCINOPHARM TAIWAN, LTD. (NA) 2013-05-16 — — WO disclosed
US-6867305-B2 Synthesis of epothilones, intermediates thereto and analogues thereof SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 2005-03-15 — — US disclosed
EP-1259490-A2 SYNTHESIS OF EPOTHILONES, INTERMEDIATES THERETO AND ANALOGUES THEREOF Sloan Kettering Institute For Cancer Research (US) 2002-11-27 — — EP disclosed
US-20020058286-A1 Synthesis of epothilones, intermediates thereto and analogues thereof NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2002-05-16 — — US disclosed
US-20020058817-A1 Synthesis of epothilones, intermediates thereto and analogues thereof NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2002-05-16 — — US disclosed
WO-2001064650-A2 SYNTHESIS OF EPOTHILONES, INTERMEDIATES THERETO AND ANALOGUES THEREOF SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH CENTER (US) 2001-09-07 — — WO disclosed
US-5633357-A Synthesis of carboxylic acid glucuronides SYNTHETIC TECHNOLOGY CORPORATION (US) 1997-05-27 — — US disclosed
US-5292899-A Synthesis of 11-nor-Δ-9-tetrahydrocannabinol-9-carboxylic acid glucuronide SYNTHETIC TECHNOLOGY CORPORATION (US) 1994-03-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140128595-A1 Process for the Preparation of ß-C-Aryl Glucosides SLC5A2, SLC5A1, UGGT1 ALDH1A1 840/4885TSHR 3962/4885LMNA 2908/4885
US-20020058817-A1 Synthesis of epothilones, intermediates thereto and analogues thereof DHPS, PPOX, THPO ALDH1A1 474/4885TSHR 2965/4885LMNA 4550/4885
US-20020058286-A1 Synthesis of epothilones, intermediates thereto and analogues thereof DHPS, PPOX, THPO ALDH1A1 474/4885TSHR 2965/4885LMNA 4550/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.